Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Sylvain Garciaz, Pierre Bories, Jean-Marie Boher, Marie Anne Hospital, Christian Récher, Colombe Saillard, Yosr Hicheri, Renato Monteiro, Olivier Hermine, Pierre Launay, Norbert Vey

Blood (2024) 144 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2024-207436

Published: 2024

Journal Articles

Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Sylvain Garciaz, Pierre Bories, Jean-Marie Boher, Marie Anne Hospital, Christian Récher, Colombe Saillard, Yosr Hicheri, Coralie Belanger, Renato Monteiro, Olivier Hermine, Pierre Launay, Norbert Vey

Blood (2023) 142 (Supplement 1): 4290.

https://doi.org/10.1182/blood-2023-185717

Published: 2023

Journal Articles

Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study

Raynier Devillier, Sabine Furst, Agnes boyer Chammard, Thomas Pagliardini, Samia Harbi, Valerio Maisano, Angela Granata, Faezeh Legrand, Jihane Pakradouni, jean Marie Boher, Cyril Fauriat, Anne-Sophie Chretien, Christian Chabannon, Norbert Vey, Eric Vivier, Daniel Olive, Didier Blaise

Blood (2021) 138 (Supplement 1): 1817.

https://doi.org/10.1182/blood-2021-150730

Published: 2021

Journal Articles

Impact of Donor Search Strategy for Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical or Matched Unrelated Donor for Patients Older Than 55 Years with Hematological Malignancies: Randomized Prospective Phase III Study

Samia Harbi, jean Marie Boher, Edouard Forcade, MD, Patrice Chevallier, MD PhD, Peffault De Latour Régis, Florent Malard, MDPhD, Sylvie Francois, MD, Amandine Charbonnier, MD, Eric Hermet, MD, Claude-Eric Bulabois, MD, Anne Huynh, Ana Berceanu, MD, Thomas Cluzeau, MDPhD, Marie Thérèse Rubio, MD PhD, Sabine Furst, Mohamad Mohty, MD PhD, Raynier Devillier, Didier Blaise, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139440

Published: 2020

Journal Articles

Low Incidence of Chronic Gvhd after Haploidentical T-Cell Replete Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide (PT-Cy)

Angela Granata, MD, Sabine Furst, MD, Jean marie Boher, Luca Castagna, MD, Patrice Chevallier, MD PhD, Alice Garnier, MD, Thierry Guillaume, MD PhD, Remy Dulery, MD, Mohamad Mohty, Faezeh Legrand, Samia Harbi, MD, Raynier Devillier, MD PhD, Catherine Faucher, MD, Stefania Bramanti, MD, Claude Lemarie, PharmD, Boris Calmels, PharmD, PhD, Pierre Jean Weiller, MD, Christian Chabannon, MD PhD, Didier Blaise, MD PhD

Blood (2016) 128 (22): 4594.

https://doi.org/10.1182/blood.V128.22.4594.4594

Published: 2016

Journal Articles

Allogeneic Stem Cell Transplantation From Matched Related Donor in Patients Over the Age of 55 Years: A Prospective Multicenter Phase II Study of a Reduced Intensity Conditioning Associating Fludarabin-IV Busulfan and Thymoglobulin

Didier Blaise, MD, Mohamad Mohty, Noel Milpied, MD, Anne Gaelle Lecorroller, PhD, Nathalie Fegueux, Sabine Furst, MD, Patrice Chevallier, MD, Reza Tabrizi, MD, Mauricette Michallet, MD, PhD, Jean Yves Cahn, MD, Anne Sirvent, MD, Jacques-Olivier Bay, MD, PhD, Jean El Cheikh, MD, PhD, Catherine Faucher, MD, Roberto Crocchiolo, MD, Agnes Boyer-Chamard, MD, Luca Castagna, MD, Jean Marie Boher, PhD

Blood (2011) 118 (21): 1952.

https://doi.org/10.1182/blood.V118.21.1952.1952

Published: 2011

Journal Articles

Natural Killer Cells Recovery After Consolidation Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML)

Jerome Rey, MD, Nicolas Anfossi, PhD, Pascale Andre, PhD, Jean-Marie Boher, Florence Orlanducci, Violette Breso, Valentine Perri, Thomas Prebet, MD, PhD, Aude Charbonnier, MD, PhD, Eloïse Perrot, Francois Romagne, PhD, Norbert Vey, MD, Daniel Olive, MD, PhD

Blood (2011) 118 (21): 2189.

https://doi.org/10.1182/blood.V118.21.2189.2189

Published: 2011

Journal Articles

Impact of the New Anti-Myeloma Drugs on Outcome of Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High-Risk Multiple Myeloma

Jean El-Cheikh, MD PhD, Roberto Crocchiolo, MD, Jean Marie Boher, PhD, Sabine Furst, MD, Anne Marie Stoppa, Catherine Faucher, MD, Luca Castagna, MD, Angela Granata, Claire Oudin, jean Marc schiano De Colella, Diane Coso, MD, Reda Bouabdallah, MD, Didier Blaise, MD

Blood (2011) 118 (21): 4456.

https://doi.org/10.1182/blood.V118.21.4456.4456

Published: 2011

Journal Articles

Phase 2 Study of Allogeneic Stem Cell Transplantation (ASCT) From Matched Related Donor (MRD) In Patients Older Than 55 Years After Reduced Intensity Conditioning (RIC) Associating Fludarabine, Intravenous Busulfan and Rabbit Thymoglobulin

Didier Blaise, MD, Mohamad Mohty, Jean Marie Boher, Noel Milpied, MD, Nathalie Fegueux, MD, Anne Sirvent, MD, Sabine Furst, Mauricette Michallet, Jean El Cheikh, Luca Castagna, Patrice Chevallier, Jacques-Olivier Bay, MD, PhD, Jean-Yves Cahn, MD, Thierry Guillaume, Reda Bouabdallah, MD, Norbert Vey, Reza Tabrizi, Christian Chabannon, MD, PhD, Catherine Faucher

Blood (2010) 116 (21): 1320.

https://doi.org/10.1182/blood.V116.21.1320.1320

Published: 2010

Journal Articles

Prospective Randomized Comparison of Reduced Intensity (FLU-BU-ATG) and Non-Myeloablative (FLU-TBI) Conditioning for Genoidentical Allo-SCT: a Clinical and economical Multicenter Itac Study.

Didier Blaise, Reza Tabrizi, Anne-Gaelle Le Corroller-Soriano, Mauricette Michallet, MD, PhD, Jacques-Olivier Bay, MD, PhD, Mohamad Mohty, MD, PhD, Catherine Faucher, MD, Sabine Furst, MD, Noel Milpied, MD, PhD, Luca Castagna, MD, Christian Chabannon, MD, PhD, Agnes Boyer, MD, Jean-Marie Boher, PhD

Blood (2009) 114 (22): 193.

https://doi.org/10.1182/blood.V114.22.193.193

Published: 2009

Journal Articles

Age and Disease Status Are Important Risk Factors for Outcome after Reduced Intensity Conditioning (RIC) Umbilical Cord Blood Transplantation (UCBT) in Adults

Sabine Fürst, Catherine Faucher, Jean El Cheikh, Jean Marie Boher, Patrick Ladaique, Claude Lemarie, Norbert Vey, Reda Bouabdallah, Anne Marie Stoppa, Hugues de Lavallade, Mohamad Mohty, Christian Chabannon, Didier Blaise

Blood (2008) 112 (11): 4412.

https://doi.org/10.1182/blood.V112.11.4412.4412

Published: 2008

NARROW

Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study

Impact of Donor Search Strategy for Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical or Matched Unrelated Donor for Patients Older Than 55 Years with Hematological Malignancies: Randomized Prospective Phase III Study

Low Incidence of Chronic Gvhd after Haploidentical T-Cell Replete Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide (PT-Cy)

Allogeneic Stem Cell Transplantation From Matched Related Donor in Patients Over the Age of 55 Years: A Prospective Multicenter Phase II Study of a Reduced Intensity Conditioning Associating Fludarabin-IV Busulfan and Thymoglobulin

Natural Killer Cells Recovery After Consolidation Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML)

Impact of the New Anti-Myeloma Drugs on Outcome of Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High-Risk Multiple Myeloma

Phase 2 Study of Allogeneic Stem Cell Transplantation (ASCT) From Matched Related Donor (MRD) In Patients Older Than 55 Years After Reduced Intensity Conditioning (RIC) Associating Fludarabine, Intravenous Busulfan and Rabbit Thymoglobulin

Prospective Randomized Comparison of Reduced Intensity (FLU-BU-ATG) and Non-Myeloablative (FLU-TBI) Conditioning for Genoidentical Allo-SCT: a Clinical and economical Multicenter Itac Study.

Age and Disease Status Are Important Risk Factors for Outcome after Reduced Intensity Conditioning (RIC) Umbilical Cord Blood Transplantation (UCBT) in Adults

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only